| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maria Thereza Gamberini, Maria Laura Bolognesi, Antonia Gladys Nasell. The modulatory role of M2 muscarinic receptor on apomorphine-induced yawning and genital grooming. Neuroscience letters. vol 531. issue 2. 2013-07-22. PMID:23041487. |
given that low doses of tripitramine increased the behavioral responses induced by apomorphine and that the main distribution of the m2 receptor is presynaptic, we raised the hypothesis that tripitramine may alter cholinergic and/or dopaminergic transmission in brain areas responsible for induction of yawning and genital grooming in rats, possibly by control of acetylcholine and/or dopamine release. |
2013-07-22 |
2023-08-12 |
rat |
| Manuela Pilleri, Konstantinos Koutsikos, Angelo Antonin. Is there room for new non-dopaminergic treatments in Parkinson's disease? Journal of neural transmission (Vienna, Austria : 1996). vol 120. issue 2. 2013-07-19. PMID:23229903. |
moreover, several non-motor disturbances, including cognition and depression are often linked to oscillation of dopamine concentrations, and are frequently relieved by treatments providing continuous dopaminergic delivery. |
2013-07-19 |
2023-08-12 |
Not clear |
| Manuela Pilleri, Konstantinos Koutsikos, Angelo Antonin. Is there room for new non-dopaminergic treatments in Parkinson's disease? Journal of neural transmission (Vienna, Austria : 1996). vol 120. issue 2. 2013-07-19. PMID:23229903. |
despite the impressive advances of pd therapeutic strategy, we think there is still need for safe, non-invasive and easily manageable dopaminergic treatments able to provide constant dopamine receptor stimulation and ensure a more stable control of dopamine responsive motor and non-motor symptoms at any stage of the disease. |
2013-07-19 |
2023-08-12 |
Not clear |
| D Sullivan, J K Pinsonneault, A C Papp, H Zhu, S Lemeshow, D C Mash, W Sade. Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction. Translational psychiatry. vol 3. 2013-07-19. PMID:23340505. |
here, we focus on the role of aberrant dopaminergic signaling, involving the dopamine transporter dat, a cocaine target, and the dopamine d2 receptor, which physically interacts with dat. |
2013-07-19 |
2023-08-12 |
human |
| A H V Schapira, F Stocchi, R Borgohain, M Onofrj, M Bhatt, P Lorenzana, V Lucini, R Giuliani, R Anan. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. European journal of neurology. vol 20. issue 2. 2013-07-18. PMID:22967035. |
safinamide is an α-aminoamide with both dopaminergic and non-dopaminergic mechanisms of action in phase iii clinical development as a once-daily add-on to dopamine agonist (da) therapy for early parkinson's disease (pd). |
2013-07-18 |
2023-08-12 |
Not clear |
| Mahlet Mersha, Rosaria Formisano, Rochelle McDonald, Pratima Pandey, Nektarios Tavernarakis, Singh Harbinde. GPA-14, a Gα(i) subunit mediates dopaminergic behavioral plasticity in C. elegans. Behavioral and brain functions : BBF. vol 9. 2013-07-18. PMID:23607404. |
in the nematode caenorhabditis elegans, the release of dopamine during behavioral plasticity is in part modulated through an acid-sensing ion channel expressed in its eight dopaminergic neurons. |
2013-07-18 |
2023-08-12 |
caenorhabditis_elegans |
| Marian E Berryhill, Martin Wiener, Jaclyn A Stephens, Falk W Lohoff, H Branch Coslet. COMT and ANKK1-Taq-Ia genetic polymorphisms influence visual working memory. PloS one. vol 8. issue 1. 2013-07-17. PMID:23383291. |
these findings link wm performance with slower dopaminergic metabolism in the prefrontal cortex as well as a greater density of dopamine receptors in the striatum. |
2013-07-17 |
2023-08-12 |
human |
| O M Littrell, J L Fuqua, A D Richardson, J Turchan-Cholewo, E R Hascup, P Huettl, F Pomerleau, L H Bradley, D M Gash, G A Gerhard. A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function. Neuropeptides. vol 47. issue 1. 2013-07-16. PMID:22981157. |
a major consequence of parkinson's disease (pd) involves the loss of dopaminergic neurons in the substantia nigra (sn) and a subsequent loss of dopamine (da) in the striatum. |
2013-07-16 |
2023-08-12 |
rat |
| Andrew J D Nelson, Karen E Thur, Helen J Cassada. Dopamine D1 receptor involvement in latent inhibition and overshadowing. The international journal of neuropsychopharmacology. vol 15. issue 10. 2013-07-15. PMID:22176724. |
there is good evidence of dopaminergic modulation of li, as the effect is reliably disrupted by the indirect dopamine (da) agonist amphetamine. |
2013-07-15 |
2023-08-12 |
Not clear |
| Elżbieta Lorenc-Koci, Tomasz Lenda, Lucyna Antkiewicz-Michaluk, Jadwiga Wardas, Helena Domin, Maria Smiałowska, Jolanta Konieczn. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats. Neurochemistry international. vol 58. issue 7. 2013-07-12. PMID:21419185. |
moreover, stereological counting of th-immunoreactive neurons and autoradiographic analysis of [(3)h]gbr 12,935 binding to dopamine transporter confirmed a loss of nigrostriatal dopaminergic neurons after an intranigral lactacystin (1 and 2.5 μg/2 μl) injection. |
2013-07-12 |
2023-08-12 |
rat |
| R Katzenschlager, K S Goerlich, T van Eimere. [Repetitive impulse-associated behavioral disorders in Parkinson's disease]. Der Nervenarzt. vol 83. issue 12. 2013-07-09. PMID:22878676. |
further behavioral disorders are the dopamine dysregulation syndrome (dds), a substance dependence characterized by craving for dopaminergic substances and punding (prolonged repetitive activities which are not goal-oriented).treatment-related risk factors are dopamine agonists for icds and a high total dopaminergic dose for dds and punding. |
2013-07-09 |
2023-08-12 |
Not clear |
| Sebastian Ocklenburg, Larissa Arning, Wanda M Gerding, Jörg T Epplen, Onur Güntürkün, Christian Best. Cholecystokinin A receptor (CCKAR) gene variation is associated with language lateralization. PloS one. vol 8. issue 1. 2013-07-09. PMID:23341962. |
since the cholecystokinin a receptor is involved in dopamine release in the central nervous system, these findings suggest that genetic variation in this receptor may modulate language lateralization due to its impact on dopaminergic pathways. |
2013-07-09 |
2023-08-12 |
human |
| David Devos, Caroline Moreau, Arnaud Delval, Kathy Dujardin, Luc Defebvre, Regis Borde. Methylphenidate : a treatment for Parkinson's disease? CNS drugs. vol 27. issue 1. 2013-07-03. PMID:23160937. |
given that the loss of dopamine in the striatum is the primary pathochemical hallmark in pd, pharmacological treatment of the disease has focused on restoring dopaminergic neurotransmission. |
2013-07-03 |
2023-08-12 |
Not clear |
| David Devos, Caroline Moreau, Arnaud Delval, Kathy Dujardin, Luc Defebvre, Regis Borde. Methylphenidate : a treatment for Parkinson's disease? CNS drugs. vol 27. issue 1. 2013-07-03. PMID:23160937. |
the currently licensed dopaminergic treatments for pd modulate all the key steps in the dopamine transmission except the most powerful determinant of extracellular dopamine concentrations: the presynaptic dopamine transporter (dat). |
2013-07-03 |
2023-08-12 |
Not clear |
| Alexander Storch, Martin Wolz, Bettina Beuthien-Baumann, Matthias Löhle, Birgit Herting, Uta Schwanebeck, Liane Oehme, Jörg van den Hoff, Maria Perick, Xina Grählert, Jörg Kotzerke, Heinz Reichman. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology. vol 80. issue 19. 2013-07-02. PMID:23576623. |
effects of dopaminergic treatment on striatal dopamine turnover in de novo parkinson disease. |
2013-07-02 |
2023-08-12 |
Not clear |
| S Ares-Santos, N Granado, R Moratall. The role of dopamine receptors in the neurotoxicity of methamphetamine. Journal of internal medicine. vol 273. issue 5. 2013-07-02. PMID:23600399. |
genetic inactivation of dopamine d1 or d2 receptors protects against the loss of dopaminergic fibres in the striatum and loss of dopaminergic neurons in the substantia nigra. |
2013-07-02 |
2023-08-12 |
mouse |
| Ginetta Collo, Federica Bono, Laura Cavalleri, Laura Plebani, Stefania Mitola, Emilio Merlo Pich, Mark J Millan, Michele Zoli, Uwe Maskos, Pierfranco Spano, Cristina Missal. Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. Molecular pharmacology. vol 83. issue 6. 2013-07-01. PMID:23543412. |
nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine d3 receptors and akt-mtorc1 signaling. |
2013-07-01 |
2023-08-12 |
mouse |
| Ginetta Collo, Federica Bono, Laura Cavalleri, Laura Plebani, Stefania Mitola, Emilio Merlo Pich, Mark J Millan, Michele Zoli, Uwe Maskos, Pierfranco Spano, Cristina Missal. Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. Molecular pharmacology. vol 83. issue 6. 2013-07-01. PMID:23543412. |
these findings indicate that nicotine-induced structural plasticity at mesencephalic dopaminergic neurons involves α4β2 nachrs together with dopamine d3r-mediated recruitment of erk/akt-mtorc1 signaling. |
2013-07-01 |
2023-08-12 |
mouse |
| A Abi-Dargha. Recent evidence for dopamine abnormalities in schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists. vol 17 Suppl 4. 2013-07-01. PMID:23573603. |
the evidence from pet and spect studies suggests that there is excess dopamine release subcortically, in the striatum, and that dopaminergic transmission may be abnormal in the cortex also, because of an upregulation in d1 receptors. |
2013-07-01 |
2023-08-12 |
Not clear |
| F Müller-Spah. Current use of atypical antipsychotics. European psychiatry : the journal of the Association of European Psychiatrists. vol 17 Suppl 4. 2013-07-01. PMID:23573608. |
at low doses it blocks presynaptic dopamine autoreceptors, inducing an increased dopaminergic neurotransmission, and at high doses it blocks postsynaptic dopaminergic activity. |
2013-07-01 |
2023-08-12 |
Not clear |